Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-VTE II
2023-508602-14-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of REGN7508 in venous thromboembolism (VTE) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of confirmed, adjudicated venous thromboembolism (VTE) through day 12. Started May 2024; status: completed.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-508602-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508602-14-00.